Tandem Diabetes Care Inc. (NASDAQ:TNDM) shares saw strong trading volume on Thursday . 216,895 shares were traded during mid-day trading, a decline of 15% from the previous session’s volume of 253,856 shares.The stock last traded at $7.84 and had previously closed at $7.94.

A number of equities research analysts have recently weighed in on the company. Zacks Investment Research raised Tandem Diabetes Care from a “hold” rating to a “buy” rating and set a $9.25 price objective for the company in a research note on Wednesday, May 4th. Robert W. Baird reiterated a “buy” rating on shares of Tandem Diabetes Care in a report on Monday, May 2nd. Piper Jaffray Cos. reiterated a “buy” rating and issued a $12.00 target price on shares of Tandem Diabetes Care in a report on Thursday, April 21st. Sterne Agee CRT reiterated a “neutral” rating on shares of Tandem Diabetes Care in a report on Monday, May 16th. Finally, Wedbush reiterated an “outperform” rating and issued a $20.00 target price on shares of Tandem Diabetes Care in a report on Wednesday, June 15th. One research analyst has rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $14.21.

The stock has a 50 day moving average price of $7.39 and a 200 day moving average price of $8.41. The firm’s market capitalization is $241.59 million.

Tandem Diabetes Care (NASDAQ:TNDM) last issued its quarterly earnings results on Thursday, April 28th. The medical device company reported ($0.68) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.69) by $0.01. The business had revenue of $20.06 million for the quarter, compared to analysts’ expectations of $17.67 million. The company’s revenue for the quarter was up 63.0% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.83) EPS. On average, analysts predict that Tandem Diabetes Care Inc. will post ($2.16) earnings per share for the current fiscal year.

Tandem Diabetes Care, Inc is a medical device company. The Company is engaged in designing, developing and commercializing products for people with insulin-dependent diabetes. The Company manufactures and sells three insulin pump products, which include t:slim Insulin Delivery System (t:slim), t:flex Insulin Delivery System (t:flex) and t:slim G4 Insulin Delivery System (t:slim G4).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.